Research dossier
Clinical research on Evening Primrose Oil (GLA)
7 trials reviewed across 4 indications.
Strongest evidence
Rheumatoid arthritis (joint pain)
Mechanism
High-dose GLA shifts eicosanoid production toward anti-inflammatory mediators (PGE1, DGLA derivatives), dampening inflammatory joint signaling.
EPO's least-weak use. The 2011 Cochrane review found 'moderate evidence' that GLA-containing oils modestly reduce RA pain and disability, supported by trials like Zurier 1996 (2.8 g/day GLA). The catch: effective doses are far higher than typical EPO capsules deliver.
Benefit needs high, sustained GLA doses (often equivalent to tens of grams of EPO daily). Standard OTC EPO dosing is unlikely to reach the studied range, and EPO is not a substitute for disease-modifying RA drugs.
Trials cited
Cochrane review — herbal therapy (incl. GLA oils) for rheumatoid arthritis
positive · Systematic review
Cameron et al., 2011, Cochrane Database of Systematic ReviewsThe least-weak indication. The Cochrane review found 'moderate evidence' that GLA-containing oils (including evening primrose) modestly reduce pain intensity and improve disability in rheumatoid arthritis. This is EPO's strongest clinical case — and it is still only modest.
Benefit required relatively high GLA doses sustained over months — far more than typical OTC EPO capsules deliver. Heterogeneous trials of variable quality.
GLA for rheumatoid arthritis (randomized trial)
positive · RCT
Zurier et al., 1996, Arthritis & Rheumatismn=56A high GLA dose (2.8 g/day) reduced RA signs and symptoms versus placebo over 6 months, with continued improvement in the open-label phase. One of the better individual trials behind the Cochrane RA conclusion.
Used 2.8 g/day of isolated GLA — equivalent to roughly 28–35 g of evening primrose oil, far beyond normal supplement dosing. The result is about high-dose GLA, not a couple of EPO capsules.
Eczema / atopic dermatitis
Mechanism
The theory: GLA bypasses a proposed delta-6-desaturase bottleneck in atopic skin, feeding anti-inflammatory prostaglandin E1. Plausible biochemistry that did not pan out clinically.
This was EPO's flagship claim and it is refuted. The 2013 Cochrane review of 27 studies (1,596 people) found no benefit over placebo. UK medicines regulators had already withdrawn EPO's eczema license (Epogam) in 2002 for lack of efficacy. The early positive trials were smaller and weaker.
No population benefits for eczema based on the pooled trial evidence. Do not use EPO as an eczema treatment.
Cochrane review — evening primrose & borage oil for eczema
Null · Systematic review
Bamford et al., 2013, Cochrane Database of Systematic Reviewsn=1596The definitive eczema verdict. Pooling 27 studies (1,596 people), oral EPO and borage oil provided no meaningful benefit over placebo for atopic eczema. Lead author Bamford: 'there is no evidence that taking either evening primrose or borage oil is of benefit to eczema sufferers.' This superseded earlier, smaller positive claims.
Some early positive trials existed and drove decades of marketing, but they were smaller and methodologically weaker; the larger pooled analysis is null.
Menopause hot flashes
Mechanism
No clear mechanism — the use is largely traditional/marketing-driven rather than physiologically grounded.
Rigorous trials are null. Chenoy 1994 (BMJ) found EPO no better than placebo for hot-flush frequency, and a 2024 meta-analysis of 4 RCTs found no significant effect on frequency or duration. A brief short-term severity signal did not persist beyond 6 months.
Not a reliable treatment for menopausal hot flashes. The evidence is described by reviewers as insufficient to draw firm conclusions.
Evening primrose oil for menopausal hot flushes
Null · RCT
Chenoy et al., 1994, BMJn=56A double-blind RCT found EPO no better than placebo for the frequency of hot flushes or night sweats. One of the first rigorous tests of the popular menopause claim, and it came back null.
Small (n=56) and only one symptom cluster, but well-designed and double-blind. Its null result has held up in later pooled analyses.
Meta-analysis — EPO for menopause hot flashes
mixed · Meta-analysis
Thevi et al., 2024, Journal of Menopausal Medicinen=292Pooling 4 RCTs (~292 women), EPO showed no significant effect on hot flash frequency or duration. A short-term (<6 months) severity reduction appeared but vanished at 6+ months. The authors concluded the evidence is 'insufficient to draw firm conclusions.' Decades after the marketing claim, the data are still weak.
Few, heterogeneous trials and a small total sample. The one positive signal (short-term severity) was inconsistent and did not persist.
PMS and cyclical breast pain (mastalgia)
Mechanism
Proposed correction of an essential-fatty-acid imbalance in PMS/mastalgia — a hypothesis the better trials have not borne out.
Once a flagship use, now largely refuted. The best mastalgia RCTs (Blommers 2002, n=120) show EPO no better than control oils, with pooled data across ~664 women reaching the same null. The highest-quality PMS trials are also null. UK regulators withdrew EPO's breast-pain license (Efamast) in 2002.
Not supported for PMS or cyclical breast pain by rigorous trials. The large placebo response in mastalgia studies is the real story.
EPO and fish oil for severe chronic mastalgia
Null · RCT
Blommers et al., 2002, American Journal of Obstetrics & Gynecologyn=120A double-blind factorial RCT in 120 women found neither EPO nor fish oil beat control oils for breast pain — all groups improved similarly. Directly undercuts the long-standing 'EPO for cyclical mastalgia' recommendation; pooled analyses across ~664 women reach the same null.
Large placebo response (all arms improved) is itself the point — mastalgia trials are dominated by regression to the mean and placebo effects that EPO does not exceed.
2 forms of Evening Primrose Oil (GLA) compared
Evening primrose oil (standardized GLA %)
Oral GLA is well absorbed; EPO is only ~8–10% GLA by weight
Best forGLA source for inflammatory and skin/hormonal claimsThe active is gamma-linolenic acid (GLA), which is only 8–10% of the oil. Look for a standardized GLA percentage on the label — a '1,000 mg EPO' capsule delivers only ~80–100 mg GLA. The RA trials used GLA doses that would require tens of grams of EPO daily.
bone2800–6000 mgCold-pressed evening primrose oil
Comparable; cold-pressing aims to preserve the fatty acids and reduce oxidation
Best forPremium positioning; same GLA activeCold-pressing and good packaging (dark capsules, antioxidants like vitamin E) reduce rancidity of these polyunsaturated oils. It does not change the underlying efficacy picture — the GLA dose and the negative trial record are the same.
Are you deficient? Symptoms, risk groups, lab tests
Side effects and drug interactions
Side effects
GI upset
Common
Nausea, soft stools, stomach discomfort — the most common complaints, usually mild.
Headache
Uncommon
Mild headaches reported in some trials, including the menopause studies.
Rancidity / oxidation
Uncommon
As a polyunsaturated oil, EPO oxidizes over time; rancid oil can cause GI upset and is pro-inflammatory. Store cool and check expiry.
Seizure-threshold concern (historical)
Rare
An old warning, traced to 1980s schizophrenia patients on antipsychotics, that EPO might lower seizure threshold. A 2007 review judged the link largely spurious, but conservative labels still advise caution in epilepsy and around surgery/anesthesia.
Drug interactions
Combined-effect risk
warfarinDOACs (apixaban, rivaroxaban)aspirinclopidogrelNSAIDsGLA's eicosanoid effects may modestly inhibit platelet aggregation, theoretically adding to blood-thinning drugs.
Use caution with anticoagulants/antiplatelets and consider stopping before surgery. The interaction is theoretical/mild but worth flagging to a prescriber.
Other
phenothiazine antipsychoticsanticonvulsantsThe historical seizure concern arose in schizophrenia patients on phenothiazines. Whether EPO meaningfully affects seizure threshold is disputed, but the legacy caution persists.
People with epilepsy or on phenothiazine antipsychotics should discuss EPO with their physician before use.
Other critical caveats
- EPO does NOT reliably treat eczema. The 2013 Cochrane review of 27 studies (1,596 people) found no benefit over placebo, and the UK Medicines Control Agency withdrew EPO's eczema license (Epogam) in 2002 for lack of efficacy. The earlier positive claims were from smaller, weaker trials.
- The menopause, PMS, and cyclical breast-pain uses are largely null in rigorous trials. UK regulators also withdrew EPO's breast-pain license (Efamast) in 2002. The big placebo response in these conditions is the real driver of perceived benefit.
- The least-weak use is rheumatoid arthritis, where pooled GLA shows 'moderate' but modest benefit — BUT the effective doses (e.g. 2.8 g GLA/day in Zurier 1996) require the equivalent of tens of grams of EPO daily, far beyond standard capsules. EPO is never a substitute for disease-modifying RA medication.
- Only ~8–10% of evening primrose oil is the active GLA. A '1,000 mg EPO' capsule supplies only ~80–100 mg GLA — read labels for the actual GLA content, not the oil weight.
- An old seizure-threshold warning (from 1980s schizophrenia patients on antipsychotics) is probably overstated, but conservative caution remains for people with epilepsy and before surgery. EPO may also mildly add to blood-thinning drugs.
Frequently asked
Does evening primrose oil help eczema?
No, not based on good evidence. A 2013 Cochrane review pooled 27 studies (1,596 people) and found EPO no better than placebo for eczema. UK medicines regulators withdrew its eczema license back in 2002 because it didn't meet the efficacy standard. The positive reputation comes from older, smaller, weaker trials.Will EPO help with menopause hot flashes, PMS, or breast pain?
The rigorous trials say no. A 2024 meta-analysis found no significant effect on hot flash frequency or duration, the classic BMJ trial (Chenoy 1994) was null, and the best mastalgia trials show EPO no better than control oils. These conditions have large placebo responses, which is likely what people are experiencing.Is there anything EPO is genuinely useful for?
Rheumatoid arthritis is the least-weak case. A Cochrane review found 'moderate evidence' that high-dose GLA (the active in EPO) modestly reduces joint pain and disability. The catch is dose: effective trials used around 2.8 g of GLA per day, which would take tens of grams of EPO — far more than a typical capsule. It's an adjunct, never a replacement for RA medication.How much GLA is actually in an EPO capsule?
Only about 8–10% of the oil is GLA, the active ingredient. So a 1,000 mg evening primrose oil capsule gives you roughly 80–100 mg of GLA. If you're chasing the doses used in arthritis research, the math doesn't work with ordinary capsules — look for the GLA content on the label, not just the oil weight.Is evening primrose oil safe?
Generally well tolerated — mild GI upset and headache are the usual complaints. There's an old caution about lowering seizure threshold (from 1980s schizophrenia patients on antipsychotics) that a 2007 review judged largely spurious, but conservative labels still advise care in epilepsy and before surgery. It may also mildly add to blood thinners, so flag it to your prescriber if you take anticoagulants.
References
- 01Bamford et al., 2013 — Oral evening primrose oil and borage oil for eczema (Cochrane)
- 02Cameron et al., 2011 — Herbal therapy for rheumatoid arthritis (Cochrane)
- 03Chenoy et al., 1994 — Gamolenic acid (EPO) for menopausal flushing (BMJ)
- 04MHRA / Medicines Control Agency — Withdrawal of Epogam and Efamast marketing authorisations, 2002
- 05Examine.com — Evening Primrose Oil
Last reviewed2026-05-24